Role of PARP inhibitors beyond BRCA mutation and platinum sensitivity in epithelial ovarian cancer: a meta-analysis of hazard ratios from randomized clinical trials

BACKGROUND: PARP inhibitors (PARPi) have a well-established role in platinum-sensitive ovarian cancer (PSOC), in BRCA mutant (BRCAm), and homologous recombination deficiency (HRD) population. However, their role in wild type and homologous recombination proficient population is still not clear. METH...

Descripción completa

Detalles Bibliográficos
Autores principales: Purwar, Roli, Ranjan, Rakesh, Pal, Manjusha, Upadhyay, Satyanshu K., Kumar, Tarun, Pandey, Manoj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10204292/
https://www.ncbi.nlm.nih.gov/pubmed/37217940
http://dx.doi.org/10.1186/s12957-023-03027-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10204292/
https://www.ncbi.nlm.nih.gov/pubmed/37217940
http://dx.doi.org/10.1186/s12957-023-03027-4

Ejemplares similares